These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34619232)

  • 1. Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients.
    Bertrand D; Hamzaoui M; Lemée V; Lamulle J; Laurent C; Etienne I; Lemoine M; Lebourg L; Hanoy M; Le Roy F; Nezam D; Farce F; Plantier JC; Boyer O; Guerrot D; Candon S
    Kidney Int; 2021 Dec; 100(6):1337-1340. PubMed ID: 34619232
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibody response to SARS-CoV-2 mRNA vaccine among kidney transplant recipients: a prospective cohort study.
    Rozen-Zvi B; Yahav D; Agur T; Zingerman B; Ben-Zvi H; Atamna A; Tau N; Mashraki T; Nesher E; Rahamimov R
    Clin Microbiol Infect; 2021 Aug; 27(8):1173.e1-1173.e4. PubMed ID: 33957273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
    Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely.
    Grupper A; Katchman H
    Am J Transplant; 2021 Aug; 21(8):2909. PubMed ID: 34080285
    [No Abstract]   [Full Text] [Related]  

  • 5. Serological response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients depends on prior exposure to SARS-CoV-2.
    Firket L; Descy J; Seidel L; Bonvoisin C; Bouquegneau A; Grosch S; Jouret F; Weekers L
    Am J Transplant; 2021 Nov; 21(11):3806-3807. PubMed ID: 34153162
    [No Abstract]   [Full Text] [Related]  

  • 6. Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients.
    Benotmane I; Gautier-Vargas G; Cognard N; Olagne J; Heibel F; Braun-Parvez L; Martzloff J; Perrin P; Moulin B; Fafi-Kremer S; Caillard S
    Kidney Int; 2021 Jun; 99(6):1487-1489. PubMed ID: 33775674
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.
    Haller MC; Kaiser RA; Langthaler S; Brandstetter C; Apfalter P; Kerschner H; Cejka D
    Transpl Int; 2021; 35():10026. PubMed ID: 35185359
    [No Abstract]   [Full Text] [Related]  

  • 8. Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.
    Schramm R; Costard-Jäckle A; Rivinius R; Fischer B; Müller B; Boeken U; Haneya A; Provaznik Z; Knabbe C; Gummert J
    Clin Res Cardiol; 2021 Aug; 110(8):1142-1149. PubMed ID: 34241676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine.
    Benotmane I; Gautier-Vargas G; Cognard N; Olagne J; Heibel F; Braun-Parvez L; Martzloff J; Perrin P; Moulin B; Fafi-Kremer S; Caillard S
    Kidney Int; 2021 Jun; 99(6):1498-1500. PubMed ID: 33887315
    [No Abstract]   [Full Text] [Related]  

  • 10. Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19.
    Benotmane I; Gautier-Vargas G; Gallais F; Gantner P; Cognard N; Olagne J; Velay A; Heibel F; Braun-Parvez L; Martzloff J; Perrin P; Moulin B; Fafi-Kremer S; Caillard S
    Am J Transplant; 2021 Nov; 21(11):3808-3810. PubMed ID: 34254431
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: No cause for alarm.
    Mossad SB
    Am J Transplant; 2021 Aug; 21(8):2908. PubMed ID: 33998136
    [No Abstract]   [Full Text] [Related]  

  • 12. Impaired Humoral Response to Third Dose of BNT162b2 mRNA COVID-19 Vaccine Despite Detectable Spike Protein-specific T cells in Lung Transplant Recipients.
    Havlin J; Skotnicova A; Dvorackova E; Hubacek P; Svorcova M; Lastovicka J; Sediva A; Kalina T; Lischke R
    Transplantation; 2022 Mar; 106(3):e183-e184. PubMed ID: 34856599
    [No Abstract]   [Full Text] [Related]  

  • 13. The SARS-CoV-2-neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccine.
    Pedersen RM; Bang LL; Tornby DS; Kierkegaard H; Nilsson AC; Johansen IS; Bistrup C; Jensen TG; Justesen US; Andersen TE
    Kidney Int; 2021 Nov; 100(5):1129-1131. PubMed ID: 34547366
    [No Abstract]   [Full Text] [Related]  

  • 14. COVID-19 in a kidney transplant recipient after mRNA-based SARS-CoV-2 vaccination.
    Tsalouchos A; Rossolini GM; Maggi L; Mazzoni A; Annunziato F; Dattolo PC
    Transpl Infect Dis; 2021 Aug; 23(4):e13649. PubMed ID: 34032340
    [No Abstract]   [Full Text] [Related]  

  • 15. A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients.
    Masset C; Benotmane I; Dantal J; Garandeau C; Gauthier-Vargas G; Cantarovich D; Meurette A; Giral M; Caillard S; Blancho G
    Kidney Int; 2022 Apr; 101(4):825-826. PubMed ID: 35167873
    [No Abstract]   [Full Text] [Related]  

  • 16. Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients.
    Al Jurdi A; Gassen RB; Borges TJ; Lape IT; Morena L; Efe O; Solhjou Z; El Fekih R; Deban C; Bohan B; Pattanayak V; Kotton CN; Azzi JR; Riella LV
    Kidney Int; 2022 Jun; 101(6):1282-1286. PubMed ID: 35429496
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients.
    Havlin J; Svorcova M; Dvorackova E; Lastovicka J; Lischke R; Kalina T; Hubacek P
    J Heart Lung Transplant; 2021 Aug; 40(8):754-758. PubMed ID: 34120839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study.
    Itzhaki Ben Zadok O; Shaul AA; Ben-Avraham B; Yaari V; Ben Zvi H; Shostak Y; Pertzov B; Eliakim-Raz N; Abed G; Abuhazira M; Barac YD; Mats I; Kramer MR; Aravot D; Kornowski R; Ben-Gal T
    Eur J Heart Fail; 2021 Sep; 23(9):1555-1559. PubMed ID: 33963635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody Response to SARS-CoV-2 mRNA Vaccine Among Kidney Transplant Recipients.
    Mungmunpuntipantip R; Wiwanitkit V
    Exp Clin Transplant; 2022 Nov; 20(11):1048. PubMed ID: 36524892
    [No Abstract]   [Full Text] [Related]  

  • 20. Delayed kinetics of SARS-CoV-2 IgG antibody production in kidney transplant recipients following the third dose of COVID-19 vaccination.
    Matsunami M; Suzuki T; Yashima J; Kuji H; Matsue K
    Clin Exp Nephrol; 2023 Jan; 27(1):98-99. PubMed ID: 35931918
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.